Class summary at a glance.

Every drug in the DMARD (Antimalarial) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $156.6Mcombined across class
Total Rx claims: 3.8M1.2M unique beneficiaries
Generic mfrs (active): 13across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Hydroxychloroquine

Brand: Plaquenil · 3.8M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 2008-01-03

13 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.164

→

Avg plan cost$0.193

Part D spend $156.6M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.